Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(EXA) stock logo
EXA
(EXA)
$24.24
$0.00
$12.34
$24.42
N/AN/A100,740 shsN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$155.35
-1.5%
$159.52
$140.68
$169.99
$374.36B0.497.92 million shs9.10 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.48
+19.7%
$7.18
$3.90
$23.86
$1.20B3.158.30 million shs14.73 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$22.38
-0.7%
$24.69
$20.92
$31.54
$126.93B0.6740.56 million shs50.75 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(EXA) stock logo
EXA
(EXA)
0.00%0.00%0.00%0.00%0.00%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.48%+0.91%-4.94%+5.98%+3.87%
Novavax, Inc. stock logo
NVAX
Novavax
+19.74%+20.71%-2.68%-21.63%+78.62%
Pfizer Inc. stock logo
PFE
Pfizer
-0.71%+1.50%-14.36%-15.41%-14.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(EXA) stock logo
EXA
(EXA)
N/AN/AN/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
4.7956 of 5 stars
3.35.04.23.93.32.50.6
Novavax, Inc. stock logo
NVAX
Novavax
3.637 of 5 stars
3.22.00.04.72.60.80.6
Pfizer Inc. stock logo
PFE
Pfizer
4.9993 of 5 stars
4.34.04.24.33.93.33.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(EXA) stock logo
EXA
(EXA)
0.00
N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.56
Moderate Buy$171.8210.61% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.43
Hold$18.00140.51% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.5732.13% Upside

Current Analyst Ratings Breakdown

Latest EXA, JNJ, NVAX, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2025
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Neutral$24.00
4/17/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$166.00 ➝ $165.00
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$181.00 ➝ $181.00
4/16/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$164.00 ➝ $169.00
4/14/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$165.00 ➝ $162.00
4/10/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$171.00 ➝ $159.00
4/9/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$163.00 ➝ $164.00
4/9/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$157.00 ➝ $172.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$28.00 ➝ $24.00
4/8/2025
Pfizer Inc. stock logo
PFE
Pfizer
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$32.00 ➝ $25.00
(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(EXA) stock logo
EXA
(EXA)
N/AN/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$89.33B4.19$12.76 per share12.17$29.69 per share5.23
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.76N/AN/A($6.04) per share-1.24
Pfizer Inc. stock logo
PFE
Pfizer
$63.63B1.99$3.51 per share6.38$15.81 per share1.42
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(EXA) stock logo
EXA
(EXA)
N/AN/A0.00N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$8.9923.3614.032.5618.20%34.24%13.63%N/A
Novavax, Inc. stock logo
NVAX
Novavax
-$545.06M-$1.33N/A93.552.85-32.18%N/A-17.05%5/9/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.4115.877.390.6412.62%19.47%8.09%4/29/2025 (Estimated)

Latest EXA, JNJ, NVAX, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.19N/AN/AN/A$204.08 millionN/A
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67N/AN/AN/A$14.43 billionN/A
4/15/2025Q1 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.59$2.77+$0.18$4.54$21.65 billion$21.89 billion
2/27/2025Q4 2024
Novavax, Inc. stock logo
NVAX
Novavax
-$0.75-$0.51+$0.24-$0.51$85.48 million$88.31 million
2/4/2025Q4 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.48$0.63+$0.15$0.07$17.26 billion$17.76 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(EXA) stock logo
EXA
(EXA)
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.203.35%+5.43%57.84%64 Years
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.69%+2.50%121.99%16 Years

Latest EXA, JNJ, NVAX, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20256/13/2025
4/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.303.37%5/27/20255/27/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(EXA) stock logo
EXA
(EXA)
N/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.43
1.11
0.86
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.93
0.93
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73

Institutional Ownership

CompanyInstitutional Ownership
(EXA) stock logo
EXA
(EXA)
74.37%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
(EXA) stock logo
EXA
(EXA)
11.53%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
(EXA) stock logo
EXA
(EXA)
N/AN/AN/ANot Optionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
152,7002.41 billion2.40 billionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990160.84 million158.58 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.67 billion5.66 billionOptionable

Recent News About These Companies

Pfizer Declares Second-Quarter 2025 Dividend
Pfizer Inc. stock logo
Pfizer (NYSE:PFE) Shares Up 1.8% - Time to Buy?
Cantor Fitzgerald Initiates a Hold Rating on Pfizer (PFE)
Pfizer Inc. stock logo
Pfizer (PFE) Projected to Post Earnings on Tuesday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
(EXA) stock logo

(EXA) NASDAQ:EXA

Exa Corporation develops, sells and supports simulation software and services that manufacturers use in design and engineering processes. The Company focuses primarily on the ground transportation market, including manufacturers in the passenger vehicle, highway truck, off-highway vehicle and train markets, as well as their suppliers. Its product, PowerFLOW, is a software solution for simulating fluid flow problems, including aerodynamics, thermal management and aeroacoustics, or wind noise. PowerFLOW uses its Digital Physics technology that enables it to predict fluid flows. PowerFLOW directly simulates unpredictable turbulent scales. The PowerFLOW software suite includes the simulation engine and grid generation engine, along with pre- and post-processing software products. The software is delivered in client/server architecture, or through its cloud-based offering, ExaCLOUD. With the ExaCLOUD solution, various client features and functions are accessed through a Web browser.

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$155.35 -2.40 (-1.52%)
Closing price 04/23/2025 03:59 PM Eastern
Extended Trading
$155.19 -0.16 (-0.10%)
As of 04/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Novavax stock logo

Novavax NASDAQ:NVAX

$7.48 +1.23 (+19.74%)
Closing price 04/23/2025 03:59 PM Eastern
Extended Trading
$7.48 -0.01 (-0.12%)
As of 04/23/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer stock logo

Pfizer NYSE:PFE

$22.38 -0.15 (-0.67%)
Closing price 04/23/2025 03:59 PM Eastern
Extended Trading
$22.42 +0.04 (+0.18%)
As of 04/23/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.